We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients...
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire SAN DIEGO and TOKYO, Nov. 20, 2024 – Kura to receive a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.88 | -8.28625235405 | 10.62 | 10.71 | 9.395 | 1483399 | 9.97136439 | CS |
4 | -6.32 | -39.3524283935 | 16.06 | 16.61 | 9.395 | 2929642 | 10.67517459 | CS |
12 | -10.47 | -51.8060366155 | 20.21 | 20.21 | 9.395 | 1381915 | 12.94403494 | CS |
26 | -10.81 | -52.603406326 | 20.55 | 23.48 | 9.395 | 996010 | 15.57309005 | CS |
52 | -2.53 | -20.619396903 | 12.27 | 24.17 | 9.395 | 1050202 | 17.57752781 | CS |
156 | -3.53 | -26.6013564431 | 13.27 | 24.17 | 7.41 | 893002 | 14.77656439 | CS |
260 | -5.14 | -34.5430107527 | 14.88 | 43 | 6.34 | 791075 | 17.56609713 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions